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Abstract Graft versus host disease (GVHD) may be abrogated and host sur-
vival prolonged by in vitro depletion ofT lymphocytes from bone marrow (BM) 
prior to allotransplantation. Using a mouse anti-rat pan T-lymphocyte mono-
clonal antibody (OX19) bound to monosized, magnetic, polymer beads, T lym-
phocytes were removed in vitro from normal bone marrow, The removal of the 
T lymphocytes was confirmed by flow cytometry. Injection of the T-lympho-
cyte-depleted bone marrow into fully allogeneic rats prevents the induction of 
GVHD and prolongs host survival. 
KeywOlcJs: Immunomagnetic T-Iymphocyte depletion, bone marrow, allo-
geneic transplantation, OX-19 monoclonal antibody, graft-versus-host disease. 
Graft-vs-host disease (GVHD) is frequently observed after bone marrow trans-
plantation and, in selected instances, following small intestinal transplantation. 1,2 
This phenomenon is thought to be due to immunocompetent donor cells, espe-
cially T lymphocytes, reacting to cells of a histoincompatible, immunologically 
comprised host. 3 Alloreactive, donor-recipient cell-cell interaction with lympho-
kine release, perhaps enhanced in an unknown way by bacteria or viruses, results 
in the pathologic damage seen in epithelial-lined organs.4- 6 A variety of tech-
niques have been used to remove the alloreactive donor T lymphocytes and pre-
vent GVHD.1- 12 However, these methods are generally complex, time-con-
suming, expensive, and in some cases nonspecific in their removal of T lympho-
cytes. They may also be toxic to the host. In this manuscript, we demonstrate 
Abbreviations: ITLD, immunomagnetic T-Iymphocyte depletion; GVHD, graft-versus-
host disease; BM, bone marrow; MoAb, monoclonal antibody; HBSS, Hank's balanced 
salt solution. 
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that binding of the pan anti-T-Iymphocyte monoclonal antibody (MoAb) OX-19 to 
monosized, magnetic polymer beads successfully removes T lymphocytes from 
rat bone marrow. This novel technique, which relies upon magnetic separation of 
T lymphocytes from bone marrow, is simple, rapid, relatively inexpensive, and 
nontoxic, and can be used in a sterile environment. 
Methods and Materials 
Animals 
Forty-five inbred AC(RTIa) and LEW(RTll) rats were bred and purchased from 
Harlan-Sprague Dawley (Indianapolis, IN). The animals were housed in conven-
tional facilities and fed commercial rat chow (Wayne Lab-Blox F-6, Chicago, IL), 
and acidified tap water ad libitum. 
T-Lymphocyte Depletion of Rat Bone Marrow 
Magnetic, mono sized polymer beads were coated with covalently bound, af-
finity-purified sheep anti-mouse IgG directed against all mouse IgG subclasses. 
(Dynal-Dynabeads M450-11001, Great Neck, NY). The beads were incubated 
with 10 f.LL fetal calf serum mg of beads (Fig IA). After 24 h of incubation at 4°C, 
the beads were washed three times in Hank's balanced salt solution (HBSS), then 
incubated with 1 f.LL of OX-19 (Accurate Chemical and Scientific Corp.) for every 
milligram of beads using the same incubation conditions (Fig lB). 
Bone marrow was harvested from the tibias and femurs of ACI rats. Cell 
counts and viability were determined using trypan blue exclusion. Viability 
always exceeded 90%. The bone marrow was incubated for 30 min at room tem-
perature with OX-19-coated beads in 5-10 mL of HBSS containing 0.05 mg/mL 
of gentamicin (Fig IC), with gentle mixing performed every 5 min. Magnetic sepa-
ration within a round-bottomed glass test tube was accomplished using a Mag-
netic Particle Concentrator (Dynal MPC-l) containing cobalt-samarium magnets. 
The bead/OX-19/T lymphocyte complexes were attracted to the magnet and 
quickly immobilized against the test tube wall (Fig ID). The supernatant, con-
taining stem cells, progenitor cells, and B cells, was easily removed from the test 
tube and the T-Iymphocyte-depleted mixture adjusted to a cell concentration of 
33.3 x 106 cells/mL for reconstitution. Bead-to-T-Iymphocyte ratios of both 20: 1 
and 60: 1 were used for T-cell depletion, based upon an estimated T-cell popula-
tion in rat bone marrow of 5%. 
Flow Cytometry 
The analysis of cell surface-associated markers by flow cytometry was conducted 
by placing 1 x 106 bone marrow cells (± ITLD) in 12 x 75-mm glass tubes in 0.1 
mL of staining buffer (PBS, pH 7.4,0.1% NA Azide, 2% FCS). The test antisera 
or normal serum was added (1: 10 to I: 100 final dilutions) for 30 min at 4°C. The 
cells were washed twice and resuspended in FITC-Iabeled anti-IgG directed 
against the primary antibody (rat anti-mouse IgG, Hand L chain specific, Boe-
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Figure 1. Preparation of immunomagnetic beads bound to OX-19 monoclonal antibody and 
the T-lymphocyte depletion technique. Step 1: The beads already bound with sheep anti-
mouse IgG are incubated for 24 h at 4°C with fetal calf serum to bind unbound, nonspecific 
sites. Step 2: OX-19 is incubated under the same conditions and attaches to the sheep 
anti-mouse IgG. Step 3: The bead/OX-19 complex binds to T lymphocytes present in the 
ACI bone marrow by virture of the affinity and avidity of the MAb for T lymphocytes. Step 
4: A cobalt-samarium magnet attracts the beads that contain 20% magnetite to the side of 
the test tube. The T lymphocytes remain bound to the OX-19 during this process. The 
supernatant is T-Iymphocyte-depleted ACl bone marrow. 
hinger-Mannheim, Indianapolis, IN). After a 30-min incubation at 4°C, the cells 
were washed twice and analyzed for fluorescence staining on an Ortho Spectrum 
III (Ortho Diagnostics, Braintree, MA) flow cytometer. Following ITLD, the 
magnetic beadllymphocyte mixture was diluted 10: I and 40: I with HBSS and 
stained by a Wright-Geimsa technique. The presence of cell-bead rosettes which 
consisted of 6-8 beads clustered as a rosette around small, mature lymphocytes 
was microscopically confirmed. 
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Figure 1. Continued. 
Reconstitution of Rat Bone Marrow 
~ 
V 
) 
Lewis rats were allowed to acclimatize for 1-2 weeks in the experimental animal 
facility and were fed acidified water containing tetracycline hydrochloride (100 
mg/L) and neomycin sulfate (10 mglL). A dose of 1000 rads of total body irradia-
tion using a I37CS source at 97 rads/min was administered to the recipient Lewis 
rat 4-6 h prior to reconstitution. The recipient was anesthetized with 3.6% 
chloral hydrate by intraperitoneal injection and surgically prepared with Betadine 
and 70% ethanol. An upper midline celiotomy was performed. The intestines 
were eviscerated and retracted to the left upper quadrant. A total of 50 x 106 
bone marrow cells from ACI rats (with or without ITLD) suspended in 1.5 mL of 
HBSS were injected into the exposed infrahepatic vena cava above the renal 
veins through a 27-gauge needle (Fig 2). Hemostasis was secured and the viscera 
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Figure 1. Continued. 
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were restored to their normal intra-abdominal position. The fascia and skin were 
closed in two layers with 4-0 Dexon. 
Recognition of GVHD 
The diagnosis of GVHD in the irradiated recipients was based upon previously 
described clinical and histopathologic findings. 13,14 All 21 recipient animals were 
assessed for clinical GVHD. An animal was considered to exhibit clinical GVHD 
if four of the following signs were observed: diffuse erythema, hyperkeratosis of 
the foot pads, dermatitis, weight loss, generalized unkempt appearance, or diar-
rhea. Ten necropsy specimens from the non-ITLD group were taken of the ear, 
tongue, liver, spleen, intestine, and mesenteric lymph nodes on days 18-25 and 
assessed for pathologic examination. Five ear biopsies from the ITLD group 
taken on days 30-60 were also examined. Specimens were processed routinely 
for light microscopy. The important microscopic histopathologic features ob-
served were the same as previously reported. 15,16 
Results 
Nonspecific Cell Loss 
Rat bone marrow contains approximately 6% T lymphocytes. 17 AI: 1 bead-to-BM 
cell ratio is approximately equivalent to a 20: 1 bead-to-BM T-Iymphocyte ratio. 
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Figure 2. Reconstitution of a lethally irradiated Lewis rat with ACI bone marrow. The 
intestines are eviscerated toward the left upper quadrant. 50 x 106 ACI cells (with or 
without ITLD) in 1.5 mL of HBSS are injected into the prehepatic vena cava through a 
27-gauge needle. 
ITLD using a ratio of 20: 1 beads to BM T lymphocytes resulted in an overall loss 
of 8-15% of the bone marrow cells. This suggests mild to moderate nonspecific 
cell binding by the beads or bead/OX-19 complexes. When a 60:1 ratio was used, 
nonspecific cell loss was 31%. Use of either of these ratios did not prevent en-
graftment of ITLD BM cells in an allogeneic host. 
Flow Cytometry 
T -lymphocyte depletion is confirmed by flow cytometric measurements which 
demonstrated at least a 1.5 10gIO depletion of T lymphocytes when compared to 
untreated ACI BM cells (Fig 3). Flow cytometric analysis of untreated ACI BM 
cells mixed with FITC conjugated OX-19 contains 5.9% T lymphocytes. Deple-
tion of the bone marrow with ITLD reduced the T lymphocytes to a maximum of 
1.8%. The percentage of T lymphocytes in this latter group may be artifactually 
elevated due to poor resolution at the lower limits of the flow cytometer capabili-
ties. 
Elimination of GVHD 
Eleven lethally irradiated Lewis rats developed severe clinical and histopatho-
logic manifestations of GVHD after transplantation with ACI BM. Ninety percent 
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Figure 3. Flow cytometric studies of ACI rat bone marrow before and after ITLD. (A) 
FITC-conjugated OX-19 is bound to untreated ACI bone marrow (5.9% T-Iymphocyte pop-
ulation of 18,772 total cells). (B) FITC-conjugated OX-19 is bound to ITLD ACI bone 
marrow (1.8% T-Iymphocyte population of 9654 total cells). Note the absence of fluores-
cent cells of the ITLD group (along the x axis) indicating the removal of T lymphocytes by 
this technique. This trial is representative of at least a 1.5 log depletion ofT lymphocytes. 
of the recipients were dead by 25 days and all were dead by 48 days. Ten lethally 
irradiated Lewis rats receiving ITLD ACI BM engrafted and survived for greater 
than 165 days. No clinical or histopathologic evidence for acute GVHD was ob-
served in this group of animals. 
The most consistent and sensitive measure of the presence of GVHD is the 
appearance of single basal epithelial cell necrosis with lymphocyte infiltration in 
the tongue and the ear (Fig 4). The livers of affected animals frequently exhibited 
lymphocytic infiltration of the portal triads with focal cellular injury to the bile 
duct epithelium. Other histopathologic changes included lymphocytic depletion 
of lymph node paracortical areas and splenic arteriolar sheaths. 
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Figure 4. Photomicrographs of the epidermis of the ear of lethally irradiated Lewis rats. 
(A) Received untreated ACI BM 22 days previously. Single epithelial cell necrosis with an 
adjacent lymphocyte (satellitosis) is seen. (H & E x 560). (B) Received ITLD ACI BM 34 
days previously. Normal epithelium. (H & E x 450). 
Immunomagnetic T-Lymphocyte Depletion 249 
Discussion 
The incidence of GVHD and the resultant morbidity and mortality to the host 
after bone marrow transplantation is eliminated by T -lymphocyte depletion of the 
donor BM.18 Various methodologies have been developed to improve the speci-
ficity and efficiency of the T-Iymphocyte depletion with variable results. These 
methods include irradiation, lectin soybean agglutination/sheep red blood cell ro-
setting, immunoabsorption using a Sepharose column, immunotoxins, comple-
ment mediated cytotoxicity, and pharmacologic inhibition. 
Irradiation successfully eliminates T lymphocytes but is nonspecific and ra-
dioresistant T -lymphocytes can be spared. 19 Physical separation techniques take 
advantage of the cell surface molecules that phenotypically identify T lympho-
cytes and their individual subsets.8- 11 Pan T, helper T, and suppressor T cell 
populations may be isolated through the use of MoAb in human or animal bone 
marrow models. T cells may be eliminated from bone marrow by sheep red blood 
cell rosetting and enhanced by soybean agglutination of the non-rosetting cell 
population. 7 Immunoabsorption of T lymphocytes using monoclonal antibodies 
bound to Sepharose is effective and has the advantage of individual subset re-
moval. However, SRBC/soybean agglutination and immunoabsorption proce-
dures are complex and time-consuming.7•10 Immunotoxins such as ricin may also 
be used; ricin linked to specific monoclonal antibodies can selectively kill T lym-
phocytes.9 Complement-fixing monoclonal or polyclonal antibodies successfully 
deplete bone marrow of T cells and inhibit GVHD, but certain complement 
systems may be toxic to bone marrow precursor cells and many monoclonal anti-
bodies, including those that define rat T-Iymphocyte subsets, do not fix comple-
ment. In addition, the immunotoxin and complement systems may harm the pro-
genitor cells or the stromal microenvironment.2o Pharmacologic methods, such as 
methotrexate and cyclophosphamide, are relatively ineffective at preventing 
GVHD in humans. GVHD has been reportedly abrogated by cyclosporine and 
anti-thymocyte globulin, but the results have been inconsistent and toxicity may 
be a concern. 21 
Monosized, magnetic polymer beads were initially developed to improve reso-
lution in liquid chromatography. The addition of magnetite (20% by weight) to the 
beads allows them to be used for magnetic separation. The surface of the bead is 
partly hydrophobic, allowing antibodies to be bound by physical adsorption, and 
partly hydrophilic due to the presence of hydroxyl groups that can be chemically 
activated to covalently bind antibodies. 20,22 
OX-19 is a MoAb derived by fusing spleen cells from a mouse immunized with 
rat thymocyte glycoproteins. The antibody detects a cell surface-associated gly-
coprotein that is present on thymocytes and mature peripheral T lymphocytes. 
OX-19 does not react with cells other than lymphoid cells in the intestine, 
thymus, spleen, and lymph nodes.23 When the OX-19lbead complex is incubated 
with rat bone marrow, T lymphocytes within the marrow bind to the MoAb-bead 
complex and magnetic separation depletes the marrow of T lymphocytes. 
The magnitude of the depletion is difficult to establish due to the small number 
of mature T lymphocytes in the bone marrow and the potential generation of 
additional T lymphocytes from the remaining progenitor cells. The percentage of 
OX-19 lymphocytes in normal ACI marrow is approximately 6% and ITLD re-
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duces the number of OX-19 cells to levels of less than 2%. This procedure has a 
potential for efficient removal of lymphocytes from the bone marrow; up to a 6 
log depletion of Rael Burkett lymphoma cells from human bone marrow has been 
obtained using 2 cycles of immunomagnetic depletion.22 Our preliminary evi-
dence that rats do not develop GVHD after receiving ITLD-treated allogeneic 
bone marrow demonstrates that the T lymphocytes have been reduced below a 
level functionally capable of inducing GVHD. 
ITLD is a novel, simple, rapidly performed in vitro technique that is nontoxic 
to the recipient. It is relatively inexpensive: 4 x 109 rat bone marrow cells can be 
depleted of T lymphocytes using 10 mL of immunomagnetic beads and small 
amounts of MoAb. The availability of specific monoclonal antibodies to a variety 
of cell surface molecules makes this immunomagnetic bead a model with a wide 
range of potential applications. 
Summary 
A highly efficient technique of T-Iymphocyte depletion using rat bone marrow is 
described. It involves the binding of OX-19, a MoAb directed against all rat thy-
mocytes and mature peripheral T lymphocytes, to monosized, magnetic polymer 
spheres. Magnetic separation of T lymphocytes after mixing the allogeneic bone 
marrow with the bead/OX-19 complex provides for a simple, rapid depletion ofT 
lymphocytes from the bone marrow. In vitro studies using flow cytometry and the 
prevention of GVHD in a fully allogeneic rat bone marrow model have been used 
to demonstrate the effectiveness of the depletion procedure. 
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